Long-Term Follow-Up Study of Psoriasis Patients

Completed

Conditions studied: Psoriasis

In brief

The purpose of this study is to evaluate the long-term safety and profile of psoriasis patients who have completed participation in a previous study and who received treatment with MEDI-507.

Key facts

Study ID

NCT00131066

Run by

MedImmune LLC

People needed

200

Starts

2002-08-01

Expected to finish

2007-12-01

Last updated by the study team

2008-09-22

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The patient has previously completed participation (i.e., completed per protocol, including any long term follow-up; or discontinued from the study due to withdrawal of consent, loss to follow-up, or other reason) in a Medimmune, Inc. study of MEDI-507 in psoriasis in which they received MEDI-507 (or placebo for patients who participated in a blinded placebo-controlled study of MEDI-507, and for whom the treatment assignment in that study has not been unblinded at the time of entry into this study)
• The patient had an absolute lymphocyte count (ALC) > 30% lower than baseline (defined as baseline prior to any MEDI-507 exposure; or, for patients whose treatment assignments have not been unblinded at the time of entry into this study, drug exposure) at his/her final visit (excluding any long-term follow-up visits) in the most recent Medimmune, Inc. study in which the patient participated; or the patient had an absolute CD4 count of < 250 cells/uL at his/her final visit (including any protocol-specific long-term follow up) in the most recent Medimmune, Inc. study in which the patient participated.
• Written informed consent obtained from the patient

You may not qualify if…

• There are no exclusion criteria.

Where it is running

• Dermatology Research Clinic — Little Rock, Arkansas, United States
• Cherry Creek Dermatology — Denver, Colorado, United States
• Atlanta Dermatology, Vein & Research Center, LLC — Alpharetta, Georgia, United States
• Future Care Studies — Springfield, Massachusetts, United States
• Washington University, Dermatology Clinical Trials Unit — St Louis, Missouri, United States
• VA Medical Center — Nashville, Tennessee, United States
• Northwest Kinetics — Tacoma, Washington, United States
• Universitaur Ziekenhuis Gent — Ghent, Belgium
• CHU Centre Ville — Liège, Belgium
• Capital District Health Authority, QE II Health Sciences Center — Halifax, Nova Scotia, Canada
• International Dermatology Research — Montreal, Quebec, Canada
• Innovaderm Research — Montreal, Canada
• Hotel Dieu/Clinque Dermatologique — Nantes, France
• Hospital Saint-Louis Service de Dermatologie 1 — Paris, France
• Hospital Haut Leveque CHU Sud -Service de Dermatologie — Pessac, France
• Universitataskilinkum der TU Dresden — Dresden, Germany
• Universitatsklinikum Hautklinik — Düsseldorf, Germany
• Klinikum de Johann - Wolfgang Goethe Universitate Frankfurt — Frankfurt, Germany
• St. Urban, Dermatologie — Freiburg im Breisgau, Germany
• Universitatsklinikum Hautklinik — Tübingen, Germany
• Academisch Medisch Centrum/Universiteit van Amsterdam (AMC/UvA) — Amsterdam, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.